FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014199603> ?p ?o ?g. }

• W2014199603 endingPage "702" @default.
• W2014199603 startingPage "696" @default.
• W2014199603 abstract "No biologic signature of chemoradiotherapy sensitivity has been reported for patients with locally advanced non-small-cell lung cancer (NSCLC). We have previously demonstrated that basic fibroblast growth factor (FGF-2) and alphavbeta3 integrin pathways control tumor radioresistance. We investigated whether the expression of the proteins involved in these pathways might be associated with the response to treatment and, therefore, the clinical outcome.FGF-2, beta3 integrin, angiopoietin-2, and syndecan-1 expression was studied using immunohistochemistry performed on biopsies obtained, before any treatment, from 65 patients exclusively treated with chemoradiotherapy for locally advanced NSCLC. The response to treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria using computed tomography at least 6 weeks after the end of the chemoradiotherapy. Local progression-free survival, metastasis-free survival, and disease-free survival were studied using the log-rank test and Cox proportional hazard analysis.Among this NSCLC biopsy population, 43.7% overexpressed beta3 integrin (beta3(+)), 43% FGF-2 (FGF-2(+)), 41.5% syndecan-1, and 59.4% angiopoietin-2. Our results showed a strong association between FGF-2 and beta3 integrin expression (p = .001). The adjusted hazard ratio of local recurrence for FGF-2(+)/beta3(+) tumors compared with FGF-2(-)/beta3(-) tumors was 6.1 (95% confidence interval, 2.6-14.6, p = .005). However, the risk of local recurrence was not increased when tumors overexpressed beta3 integrin or FGF-2 alone. Moreover, the co-expression of these two proteins was marginally associated with the response to chemoradiotherapy and metastasis-free survival.The results of this study have identified the combined profile FGF-2/beta3 integrin expression as a signature of local control in patients treated with chemoradiotherapy for locally advanced NSCLC." @default.
• W2014199603 created "2016-06-24" @default.
• W2014199603 creator A5005242998 @default.
• W2014199603 creator A5006552617 @default.
• W2014199603 creator A5010912611 @default.
• W2014199603 creator A5014724875 @default.
• W2014199603 creator A5046580775 @default.
• W2014199603 creator A5046841549 @default.
• W2014199603 creator A5055246540 @default.
• W2014199603 creator A5060829795 @default.
• W2014199603 creator A5082689339 @default.
• W2014199603 creator A5088902356 @default.
• W2014199603 date "2009-11-01" @default.
• W2014199603 modified "2023-10-16" @default.
• W2014199603 title "Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer" @default.
• W2014199603 cites W1498354922 @default.
• W2014199603 cites W1676589588 @default.
• W2014199603 cites W1734622341 @default.
• W2014199603 cites W1936643702 @default.
• W2014199603 cites W1964284552 @default.
• W2014199603 cites W1972024414 @default.
• W2014199603 cites W1975843217 @default.
• W2014199603 cites W1995567710 @default.
• W2014199603 cites W1998502003 @default.
• W2014199603 cites W2004718750 @default.
• W2014199603 cites W2029320277 @default.
• W2014199603 cites W2032131447 @default.
• W2014199603 cites W2032382187 @default.
• W2014199603 cites W2044136921 @default.
• W2014199603 cites W2047987451 @default.
• W2014199603 cites W2060985892 @default.
• W2014199603 cites W2071667499 @default.
• W2014199603 cites W2075880806 @default.
• W2014199603 cites W2079252535 @default.
• W2014199603 cites W2083771852 @default.
• W2014199603 cites W2105202429 @default.
• W2014199603 cites W2105969273 @default.
• W2014199603 cites W2115538252 @default.
• W2014199603 cites W2127449225 @default.
• W2014199603 cites W2133854223 @default.
• W2014199603 cites W2135299677 @default.
• W2014199603 cites W2137737798 @default.
• W2014199603 cites W2138178697 @default.
• W2014199603 cites W2150386316 @default.
• W2014199603 cites W2159755902 @default.
• W2014199603 cites W2160433100 @default.
• W2014199603 cites W2166351918 @default.
• W2014199603 cites W2168072083 @default.
• W2014199603 cites W2222961311 @default.
• W2014199603 cites W2240137530 @default.
• W2014199603 cites W2313149858 @default.
• W2014199603 cites W2331825483 @default.
• W2014199603 cites W2401777821 @default.
• W2014199603 cites W2402715684 @default.
• W2014199603 doi "https://doi.org/10.1016/j.ijrobp.2008.11.050" @default.
• W2014199603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19386436" @default.
• W2014199603 hasPublicationYear "2009" @default.
• W2014199603 type Work @default.
• W2014199603 sameAs 2014199603 @default.
• W2014199603 citedByCount "18" @default.
• W2014199603 countsByYear W20141996032012 @default.
• W2014199603 countsByYear W20141996032013 @default.
• W2014199603 countsByYear W20141996032014 @default.
• W2014199603 countsByYear W20141996032016 @default.
• W2014199603 countsByYear W20141996032018 @default.
• W2014199603 crossrefType "journal-article" @default.
• W2014199603 hasAuthorship W2014199603A5005242998 @default.
• W2014199603 hasAuthorship W2014199603A5006552617 @default.
• W2014199603 hasAuthorship W2014199603A5010912611 @default.
• W2014199603 hasAuthorship W2014199603A5014724875 @default.
• W2014199603 hasAuthorship W2014199603A5046580775 @default.
• W2014199603 hasAuthorship W2014199603A5046841549 @default.
• W2014199603 hasAuthorship W2014199603A5055246540 @default.
• W2014199603 hasAuthorship W2014199603A5060829795 @default.
• W2014199603 hasAuthorship W2014199603A5082689339 @default.
• W2014199603 hasAuthorship W2014199603A5088902356 @default.
• W2014199603 hasConcept C121608353 @default.
• W2014199603 hasConcept C126322002 @default.
• W2014199603 hasConcept C142724271 @default.
• W2014199603 hasConcept C143998085 @default.
• W2014199603 hasConcept C204232928 @default.
• W2014199603 hasConcept C207103383 @default.
• W2014199603 hasConcept C2776256026 @default.
• W2014199603 hasConcept C2778424827 @default.
• W2014199603 hasConcept C2779013556 @default.
• W2014199603 hasConcept C2908647359 @default.
• W2014199603 hasConcept C44249647 @default.
• W2014199603 hasConcept C502942594 @default.
• W2014199603 hasConcept C71924100 @default.
• W2014199603 hasConcept C99454951 @default.
• W2014199603 hasConceptScore W2014199603C121608353 @default.
• W2014199603 hasConceptScore W2014199603C126322002 @default.
• W2014199603 hasConceptScore W2014199603C142724271 @default.
• W2014199603 hasConceptScore W2014199603C143998085 @default.
• W2014199603 hasConceptScore W2014199603C204232928 @default.
• W2014199603 hasConceptScore W2014199603C207103383 @default.
• W2014199603 hasConceptScore W2014199603C2776256026 @default.
• W2014199603 hasConceptScore W2014199603C2778424827 @default.

• next